CD274 and non-small cell lung carcinoma: ICIs have also become pivotal in the management of locally advanced NSCLC following the PACIFIC trial, which found a progression-free-survival (PFS) of 16.8 months among patients with unresectable stage III NSCLC treated with chemoradiotherapy and adjuvant durvalumab (anti-PD-L1) compared to 5.6 months in the placebo arm [6].